Boellner v. Clinical Study Centers, LLC

2011 Ark. 83, 378 S.W.3d 745, 2011 Ark. LEXIS 73
CourtSupreme Court of Arkansas
DecidedFebruary 24, 2011
DocketNo. 10-348
StatusPublished
Cited by36 cases

This text of 2011 Ark. 83 (Boellner v. Clinical Study Centers, LLC) is published on Counsel Stack Legal Research, covering Supreme Court of Arkansas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Boellner v. Clinical Study Centers, LLC, 2011 Ark. 83, 378 S.W.3d 745, 2011 Ark. LEXIS 73 (Ark. 2011).

Opinion

COURTNEY HUDSON HENRY, Justice.

|,Appellants Samuel Boellner, M.D., and Marilyn Boellner appeal a Pulaski County jury’s verdict in favor of appellees Clinical Study Centers, LLC (CSC); Dr. John Giblin; Dr. Anthony Johnson; and Dr. Gordon Gibson. For reversal, appellants argue that substantial evidence does not support the jury’s verdicts on tortious interference with business expectancy, breach of contract, defamation, and damages. Appellants also challenge the circuit court’s jury instructions. On cross-appeal, appellees argue that the exemption statute for an individual retirement account (IRA), contained in Arkansas Code Annotated section 16-66-220(a)(l) (Repl.2005), conflicts with the plain language of article 9, section 2 of the Arkansas Constitution. Our jurisdiction is proper pursuant to Arkansas Supreme Court Rule 1 — 2(a)(1) (2010). We affirm both on direct appeal and on cross-appeal. .

| gI. Facts

On February 19, 1998, appellant Samuel Boellner (Boellner) founded CSC to perform drug studies or clinical trials for certain pharmaceutical companies. CSC performed these clinical trials under the authority of and oversight by the Federal Drug Administration (FDA). FDA regulations require that each clinical study be conducted by a principal investigator (PI), who agrees to conduct or supervise the study in accordance with FDA regulations and protocol. Institutional review boards (IRBs) review, approve, and monitor proposed research protocols. Under FDA regulations, an IRB must approve, monitor, and review each clinical study involving biomedical research.

From CSC’s formation in 1997 until August 1, 2006, Boellner served as CSC’s chief executive officer. In 2000, Gibson joined CSC and became a fifty percent (50%) owner. On August 1, 2006, Boellner and Gibson agreed to transfer ninety-two percent (92%) of their collective ownership in CSC to Giblin, Johnson, and Bryan Jeffrey, a certified public accountant, for the sale price of $150,000. Gibson retained four percent (4%) ownership. As part of the agreement, Boellner became a consultant by contract and retained four percent (4%) ownership in CSC. Under the sale contract, Boellner received an annual consulting fee of $60,000 and additional compensation on a negotiated basis for new studies beginning July 31, 2006. In 2007, Boellner served as a PI for two studies: Arkansas IRB, which was sponsored by Abbott Laboratories, and Copernicus Group IRB, which was sponsored by Shire Pharmaceuticals.

| sWithin two months of CSC’s sale, Boellner expressed his dissatisfaction with the purchase of CSC and its new management. After January 1, 2007, CSC made no payments to Boellner for his fixed consulting fee or for his percentage of new study revenues. According to appellees’ complaint, from January 2007 through June 25, 2007, Boellner engaged in a systematic pattern of conduct that included demands for personal compensation without regard for company priorities, such as rent, payroll, utilities, and salaries. Appel-lees alleged that their attempts to discuss financial issues brought (1) threats by Boellner to cancel studies; (2) personal calls to client sponsors; (3) absenteeism; (4) refusal to sign documents; (5) and harassment of sponsors’ financial representatives, study monitors, and clinic staff. According to appellees, Boellner directed personal slurs, profanity, and insults directly toward Giblin and Johnson. Boell-ner’s conduct allegedly continued until his termination, despite appellees’ attempts to satisfy Boellner’s financial demands. The parties allegedly reached a verbal agreement, but Boellner disavowed the agreement the following day. On June 25, 2007, CSC terminated its consulting agreement with Boellner. As a result of the termination, CSC informed Boellner that he no longer remained the PI on the studies monitored by Arkansas IRB or Copernicus IRB. CSC also denied Boellner access to his office and the monitoring facilities.

On that same day, Boellner sent a letter to the chairperson of Copernicus IRB, notifying the IRB of CSC’s actions and that Giblin, the newly proposed PI, was “under weekly follow-up treatment for previous drug abuse.” Boellner continued that, although he | Relieved Giblin “[was] very capable as an investigator, [Boellner] questioned] if [Giblin] should be the principal investigator on a study with a controlled substance.” Subsequently, on July 3, 2007, Boellner also faxed a letter to Dr. John E. Slaven, chairperson of Arkansas IRB, with a copy to the study sponsor. In the letter, Boellner notified the IRB of CSC’s actions and that Giblin, its new PI, was required by the Arkansas State Medical Board to “attend a weekly drug abuse program which he still attends and receives frequent random drug tests.”

On August 6, 2007, appellees filed a complaint against appellants for breach of contract, tortious interference with business expectancy, defamation, and declaratory judgment on the parties’ agreement. Specifically, appellees alleged (1) breaches of contract for a covenant not to compete, a nonsolicitation agreement, and a confidentiality agreement; (2) tortious interference with business expectancy; (3) defamation; (4) and injunctive relief. Giblin asserted a separate claim for defamation against Boellner. On September 5, 2007, appellants counterclaimed for breach of contract, wrongful termination, and declaratory judgment on the noncompete agreement.

The circuit court held a jury trial in Pulaski County Circuit Court in June 2009. During the jury-instruction conference, ap-pellees conceded that they did not have a breach-of-contract claim against Marilyn Boellner and dropped the claim. At the conclusion of the trial, the jury returned the following awards: (1) $325,000 to ap-pellees for breach of contract against Boellner; (2) $825,000 to appellees for tor-tious interference with business expectancy | ^against appellants; (3) $325,000 in punitive damages for tortious interference with business expectancy to appellees against Boellner; (4) $75,600 in compensatory damages for defamation to Giblin against Boellner; and (5) $250,000 in punitive damages for defamation to Giblin against Boellner. The jury also returned verdicts in favor of Boellner in the amount of $403,696.04. On July 21, 2009, the circuit court entered its order reflecting these jury awards. After applying a credit toward the verdict based upon Boellner’s recovery, the court awarded judgment in favor of appellees in the amount of $571,202.96. The court also entered a judgment in favor of Giblin against Boell-ner for a total amount of $325,600.

On August 4, 2009, appellants timely filed posttrial motions for JNOV, remitti-tur, and new trial, which the court orally denied from the bench on August 24, 2009. The circuit court did not enter an order within thirty days; therefore, the motions were later deemed denied. Appellants timely filed a notice of appeal on September 23, 2009.

Appellees learned, during the course of postjudgment discovery and collection proceedings, that Boellner owned an IRA valued in excess of $1.1 million at the time of the judgment. Boellner filed a brief in support of claimed exemptions, arguing that this account was exempt from collection. Appellees responded with an objection to the claimed exemption and a motion to declare Arkansas Code Annotated section 16-66-220(a)(l) unconstitutional. In their motion, appellees argued that the circuit court should not exempt the IRA because the statute is in conflict with article 9, section 2 of the Arkansas Constitution.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Swillie v. Cooper
E.D. Arkansas, 2025
Pitts v. Payne
E.D. Arkansas, 2024
Reece v. Bank of N.Y. Mellon
381 F. Supp. 3d 1009 (E.D. Arkansas, 2019)
Terry v. G4S Secure Solutions (Usa) Inc.
366 F. Supp. 3d 1060 (E.D. Arkansas, 2019)
Chambers v. McDougald
2017 Ark. App. 357 (Court of Appeals of Arkansas, 2017)
Rudy Webb v. Exxon Mobil Corporation
856 F.3d 1150 (Eighth Circuit, 2017)
Washington v. Kingridge Enterprises, Inc.
2014 Ark. App. 705 (Court of Appeals of Arkansas, 2014)
Millsap v. Williams
2014 Ark. 469 (Supreme Court of Arkansas, 2014)
Cozart v. Logue
2014 Ark. App. 626 (Court of Appeals of Arkansas, 2014)
Arkansas Realtors Ass'n v. Real Forms, LLC
2014 Ark. 385 (Supreme Court of Arkansas, 2014)
Phillips v. Phillips
2014 Ark. App. 486 (Court of Appeals of Arkansas, 2014)
Trakru v. Mathews
2014 Ark. App. 154 (Court of Appeals of Arkansas, 2014)
King v. Carter
2013 Ark. App. 749 (Court of Appeals of Arkansas, 2013)
Worden v. Kirchner
2013 Ark. 509 (Supreme Court of Arkansas, 2013)
Marlow v. United Sys. of Ark. Inc.
2013 Ark. 460 (Supreme Court of Arkansas, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
2011 Ark. 83, 378 S.W.3d 745, 2011 Ark. LEXIS 73, Counsel Stack Legal Research, https://law.counselstack.com/opinion/boellner-v-clinical-study-centers-llc-ark-2011.